Last edition
News about "Alzheimer Disease"
Johnson & Johnson Receives FDA Fast Track Designations for Treatment of Alzheimer's Disease
Posdinemab is the second Fast Track designation granted in 2024 for the Company’s AD portfolio.
Alzheimer Disease | 10/01/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members